59660-56-9

Usage

Uses

Used in Fluorescent Dyes and Sensors:
2,1,3-Benzoxadiazol-5-ylmethanol is used as a building block for the synthesis of fluorescent dyes and sensors. Its high quantum yield and photostability make it an ideal component for creating sensitive and reliable detection tools.
Used in Fluorescence Microscopy:
As a fluorescent probe, 2,1,3-Benzoxadiazol-5-ylmethanol is utilized in fluorescence microscopy for the detection of DNA and protein interactions. Its properties allow for clear and stable imaging, enhancing the study of biological processes at the molecular level.
Used in Analytical Chemistry:
In the field of analytical chemistry, 2,1,3-Benzoxadiazol-5-ylmethanol is employed for its ability to be functionalized, enabling the development of new analytical methods and techniques for detecting and quantifying various substances.
Used in Materials Science:
2,1,3-Benzoxadiazol-5-ylmethanol is also used in materials science, where its fluorescent properties can be incorporated into the design and synthesis of new materials with specific optical and electronic properties.
Used in Biochemistry:
In biochemistry, 2,1,3-Benzoxadiazol-5-ylmethanol serves as a versatile molecule that can be modified for various applications, such as the development of new biochemical assays and the study of enzyme mechanisms.

InChI:InChI=1/C7H6N2O2/c10-4-5-1-2-6-7(3-5)9-11-8-6/h1-3,10H,4H2

Upstream product

• 32863-31-3 5-(bromomethyl)benzofurazan 
• 19164-42-2 5-formylbenzo[c][1,2,5]oxadiazole 1-oxide 
• 229322-23-0 6-(hydroxymethyl)benzo<1,2-c>1,2,5-oxadiazole N₁-oxide 
• 104-88-1 4-chlorobenzaldehyde 
• 16588-34-4 4-chloro-3-nitro-benzaldehyde 
• 19155-93-2 4-azido-3-nitrobenzaldehyde 
• 32863-33-5 5-formylbenzofurazan 
• 459-57-4 4-fluorobenzaldehyde 
• 42564-51-2 4-fluoro-3-nitrobenzaldehyde 
• 57948-15-9 5-formylbenzo[1,2-c]1,2,5-oxadiazole N¹-oxide 

Downstream Products

• 32863-31-3 5-(bromomethyl)benzofurazan 
• 32863-33-5 5-formylbenzofurazan 

Relevant academic research and scientific papers

Piperidine compound and preparation method and medical application thereof

The invention discloses a piperidine compound shown as a formula (I) and a preparation method and medical application thereof, and particularly relates to a piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof and a preparation method and application of the piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof. The compound provided by the invention can inhibit the activity of USP7 enzyme, has very good selectivity and druggability, and can be used for preparing medicines for preventing or treating tumor diseases or virus infectious diseases.

Biphenyl compound as well as preparation method and medical application thereof

The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.

Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity

A series of phenoxybutanoic acid derivatives were synthesized and tested for their antagonistic activity on the contraction of the rat thoracic aortic ring induced by endothelin-1. Preliminary screening results showed that 6e and 6g with benzoheterocycles demonstrated significant antagonistic activities when compared to the reference compound BQ123. The results from additional assays for the binding affinity and selectivity for endothelin receptors showed that 6e was a selective ETA antagonist with a nanomolar IC50. Moreover, 6e was effective in relieving hypoxia-induced pulmonary arterial hypertension and right ventricular weight ratio. Therefore, 6e may have potential for further development as a therapeutic agent for the treatment of cardiovascular diseases.

PYROLLIDINE-BASED COMPOUNDS

The present invention discloses the compounds of formula ( I ) or a pharmaceutically acceptable derivative, salt or prodrug thereof, which can inhibit HIV replication.

PYROLLIDINE-BASED COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof, which can inhibit HIV replication.

In vivo anti-chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives

New benzofuroxans were developed and studied as antiproliferative Trypanosoma cruzi agents. Compounds displayed remarkable in vitro activities against different strains, Tulahuen 2, CL Brener and Y. Its unspecific cytotoxicity was evaluated using human macrophages being not toxic at a concentration at least 8 times, and until 250 times, that of its T. cruzi IC50. Some biochemical pathways were studied, namely parasite respiration, cysteinyl active site enzymes and reaction with glutathione, as target for the mechanism of action. Not only T. cruzi respiration but also Cruzipain or trypanothione reductase were not affected, however the most active derivatives, the vinylsulfinyl- and vinylsulfonyl-containing benzofuroxans, react with glutathione in a redox pathway. Furthermore, the compounds showed good in vivo activities when they were studied in an acute murine model of Chagas' disease. The compounds were able to reduce the parasite loads of animals with fully established T. cruzi infections.

Benzofurazanyl- and benzofuroxanyl-1,4-dihydlropyridines : Synthesis, structure and calcium entry blocker activity

The synthesis, structural characterization and calcium blocking activity of a series of benzofurazanyl-1,4-dihydropyridines (18 and 19) and benzofuroxanyl analogues (20 and 21) are reported. 1H-NMR showed that all the benzofuroxan derivatives exist in solution as tautomeric mixtures. The predominant tautomeric form in solution of the derivative 20 (dimethyl 1,4-dihydro-2,6-dimethyl-4-(4-benzofuroxanyl)-3,5-pyridinedicarboxylate) is also the one preferred in the solid state as shown by X-ray analysis. The conformation in the solid state of the benzofurazanyl analogue is also reported. Calcium entry blocker activity of the dihydropyridine derivatives 18-21 has been evaluated in isolated rabbit basilar artery as relaxation of calcium-induced contractions in high K+-depolarizing solution. All the compounds displayed high potency. The activity of benzofurazan derivatives was not changed by the N-oxidation. The two most active compounds 18 and 20 were as potent as Nifedipine.